PAVmed (PAVM) Preferred Stock Liabilities (2025)
PAVmed's (PAVM) quarterly Preferred Stock Liabilities came in at $3.3 million in Q3 2025, down 84.28% quarter-over-quarter from $20.7 million in Q2 2025.
PAVmed (PAVM) Preferred Stock Liabilities (2025) Analysis & Trends
PAVmed's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $3.3 million for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | PAVmed | 11.39 Mn | 9.86 Mn | -4,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 20.73 Mn |
| Mar 31, 2025 | 19.15 Mn |